B Cell Subset Composition Segments Clinically and Serologically Distinct Groups in Chronic Cutaneous Lupus Erythematosus
Overview
Authors
Affiliations
Objective: While the contribution of B-cells to SLE is well established, its role in chronic cutaneous lupus erythematosus (CCLE) remains unclear. Here, we compare B-cell and serum auto-antibody profiles between patients with systemic lupus erythematosus (SLE), CCLE, and overlap conditions.
Methods: B-cells were compared by flow cytometry amongst healthy controls, CCLE without systemic lupus (CCLE+/SLE-) and SLE patients with (SLE+/CCLE+) or without CCLE (SLE+/CCLE-). Serum was analyed for autoreactive 9G4+, anti-double-stranded DNA, anti-chromatin and anti-RNA antibodies by ELISA and for anti-RNA binding proteins (RBP) by luciferase immunoprecipitation.
Results: Patients with CCLE+/SLE- share B-cell abnormalities with SLE including decreased unswitched memory and increased effector B-cells albeit at a lower level than SLE patients. Similarly, both SLE and CCLE+/SLE- patients have elevated 9G4+ IgG autoantibodies despite lower levels of anti-nucleic acid and anti-RBP antibodies in CCLE+/SLE-. CCLE+/SLE- patients could be stratified into those with SLE-like B-cell profiles and a separate group with normal B-cell profiles. The former group was more serologically active and more likely to have disseminated skin lesions.
Conclusion: CCLE displays perturbations in B-cell homeostasis and partial B-cell tolerance breakdown. Our study demonstrates that this entity is immunologically heterogeneous and includes a disease segment whose B-cell compartment resembles SLE and is clinically associated with enhanced serological activity and more extensive skin disease. This picture suggests that SLE-like B-cell changes in primary CCLE may help identify patients at risk for subsequent development of SLE. B-cell profiling in CCLE might also indentify candidates who would benefit from B-cell targeted therapies.
Organ-based characterization of B cells in patients with systemic lupus erythematosus.
Wang Y, Zhao R, Liang Q, Ni S, Yang M, Qiu L Front Immunol. 2025; 16:1509033.
PMID: 39917309 PMC: 11798990. DOI: 10.3389/fimmu.2025.1509033.
Aubergeon L, Felten R, Gottenberg J, Dumortier H, Monneaux F Cells. 2025; 13(24.
PMID: 39768154 PMC: 11674271. DOI: 10.3390/cells13242063.
Montamat G, Meehan C, Bradford H, Yildirim R, Guimaraes F, Johnson M Clin Exp Immunol. 2024; 219(1).
PMID: 39658056 PMC: 11773804. DOI: 10.1093/cei/uxae119.
Zhang L, Yu L, Li Q, Ni M, Dong Q, Bao Y Clin Rheumatol. 2024; 44(1):217-227.
PMID: 39537946 DOI: 10.1007/s10067-024-07231-9.
Faliti C, Van T, Anam F, Cheedarla N, Williams M, Mishra A Nat Immunol. 2024; 26(1):131-145.
PMID: 39533072 PMC: 11695260. DOI: 10.1038/s41590-024-02010-9.